{
    "paper_id": "PMC4358410",
    "metadata": {
        "title": "FDA approved drugs as potential Ebola treatments",
        "authors": [
            {
                "first": "Sean",
                "middle": [],
                "last": "Ekins",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Megan",
                "middle": [],
                "last": "Coffee",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "As the Ebola outbreak continues and the costs spiral\n1 we should perhaps be considering what alternative treatments are close to hand in Africa to complement the public health measures that have been used to date\n2. Two independent studies funded by the US Defense Threat Reduction Agency in 2013 identified FDA approved drugs worthy of further evaluation. This work now seems prescient although it appears to have not been followed through to any public conclusion.",
            "cite_spans": [
                {
                    "start": 53,
                    "end": 54,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 213,
                    "end": 214,
                    "mention": "2",
                    "ref_id": "BIBREF11"
                }
            ],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "In one study, the antimalarials amodiaquine and chloroquine (\nFigure 1) were found to be active using\nin vitro cell culture assays and an\nin vivo mouse model\n3. Both drugs are cheap, generally safe, and likely readily accessible in Africa. These compounds have also shown relatively broad activity against other viruses\nin vitro and\nin vivo in animal models (Dengue, Coronavirus OC43, SARS etc.)\n4\u2013\n7. A second study suggested selective estrogen receptor modulators (SERM) clomiphene and toremifene (\nFigure 1) as inhibitors of Ebola virus\n8. The latter compounds are likely more accessible in the west and indicates that other FDA or EMEA approved drugs may be worth testing including those with hormonal effects that are SERMs. More recent work from 2014 in Europe identified a further 3 FDA drugs, amiodarone, dronedarone and verapamil (\nFigure 1) that inhibit filovirus entry at plasma levels attainable in humans\n9. The mechanism of action for most of these drugs is unknown although, using computational methods we have recently shown that the antimalarials and SERMs may share some pharmacophore features which may be important to infer a potential common target or targets\n10. To our knowledge likely well over 100 small drug-like molecules have now been identified with activity against the Ebola virus including over 50 FDA drugs derived from a reporter assay at NCATS\n11\u2013\n15.",
            "cite_spans": [
                {
                    "start": 158,
                    "end": 159,
                    "mention": "3",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 396,
                    "end": 397,
                    "mention": "4",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 399,
                    "end": 400,
                    "mention": "7",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 540,
                    "end": 541,
                    "mention": "8",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 918,
                    "end": 919,
                    "mention": "9",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 1181,
                    "end": 1183,
                    "mention": "10",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1379,
                    "end": 1381,
                    "mention": "11",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1383,
                    "end": 1385,
                    "mention": "15",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "",
            "ref_spans": [
                {
                    "start": 62,
                    "end": 70,
                    "mention": "Figure 1",
                    "ref_id": null
                },
                {
                    "start": 501,
                    "end": 509,
                    "mention": "Figure 1",
                    "ref_id": null
                },
                {
                    "start": 841,
                    "end": 849,
                    "mention": "Figure 1",
                    "ref_id": null
                }
            ]
        },
        {
            "text": "As we await the development of a vaccine or biologic could we consider assessing the efficacy of the antimalarials or the other \u2018FDA approved drugs\u2019, as either treatments or prophylactics to prevent the Ebola virus from spreading further? While there can be no guarantee they will work (perhaps requiring adjusted dosage) they may be a last resort. It is possible there are other \u201cnon-antivirals\u201d that are widely used in Africa that may also be effective against Ebola. Another example of where \u2018non-antiviral\u2019 FDA approved drugs have been found to have \u2018anti-viral activity\u2019 is for Hepatitis Virus B and D where the sodium taurocholate co-transporting polypeptide (NTCP) was identified as a receptor\n16 and screening produced drugs such as azelastine, pioglitazone, glyburide, irbesartan and ezetimibe that inhibited the transporter and may provide potential treatments\n17,\n18. Of these compounds, azelastine has been shown to possess\nin vitro activity against Hepatitis Virus B to date\n18.",
            "cite_spans": [
                {
                    "start": 701,
                    "end": 703,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 871,
                    "end": 873,
                    "mention": "17",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 875,
                    "end": 877,
                    "mention": "18",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 988,
                    "end": 990,
                    "mention": "18",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "The aforementioned screens of \u2018FDA approved drugs\u2019\n3,\n8,\n9 for Ebola virus activity, were far from comprehensive, covering only some of the known approved drugs currently in use. In an age where drug repurposing is in vogue\n19\u2013\n23 and it can be facilitated by computational methods\n24\u2013\n26, it would seem a valuable resource for finding compounds active against the Ebola virus. For example, the recent pharmacophores developed for Ebola\n10 and virtual screens\n11 could be used to computationally search larger datasets of FDA approved drugs and prioritize additional compounds for testing\nin vitro. Even using the known actives (\nFigure 1) to perform simple similarity searches in a set of over 1300 Approved Drugs in a mobile app (\nhttp://molmatinf.com/approveddrugs.html) could prioritize further compounds for testing (\nFigure S1\u2013\nFigure S7). For example molecules with structural similarity to chloroquine (\nFigure S1) not only includes known actives like amodiaquine and hydroxychloroquine\n3 but also suggests the antimalarials primaquine, halofantrine and the antihistamine chlorpheniramine. Molecules with similarity to amodiaquine include the kinase inhibitors neratinib and gefitinib while other kinase inhibitors have been suggested as having activity against Ebola virus\n15, these may not be readily accessible in Africa. Other compounds retrieved by similarity include the antimicrobial pentamidine (\nFigure S3,\nFigure S4,\nFigure S7), the antiemetic trimethobenzamide (\nFigure S3\u2013\nFigure S7) and the antihistamine doxylamine (\nFigure S5). Certainly more sophisticated and exhaustive searches than this could be tried. Deciding which molecules to use or test should also involve the physician\u2019s perspective\n27. Alternative treatments may also be found by studying those close to patients who may not have contracted the disease and are taking a drug for another chronic disease. Whether we can find a treatment for Ebola by serendipity is questionable but some of the published studies with known drugs might point us in the right direction of where to look. The opportunity to put already available drugs like those already identified\n3,\n8,\n9,\n11\u2013\n14 back on the table may be a useful tool for frontline doctors to have and is worthy of more urgent discussion and research.",
            "cite_spans": [
                {
                    "start": 51,
                    "end": 52,
                    "mention": "3",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 54,
                    "end": 55,
                    "mention": "8",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 57,
                    "end": 58,
                    "mention": "9",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 224,
                    "end": 226,
                    "mention": "19",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 228,
                    "end": 230,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 282,
                    "end": 284,
                    "mention": "24",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 286,
                    "end": 288,
                    "mention": "26",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 437,
                    "end": 439,
                    "mention": "10",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 460,
                    "end": 462,
                    "mention": "11",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 995,
                    "end": 996,
                    "mention": "3",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1282,
                    "end": 1284,
                    "mention": "15",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 1718,
                    "end": 1720,
                    "mention": "27",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 2147,
                    "end": 2148,
                    "mention": "3",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 2150,
                    "end": 2151,
                    "mention": "8",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 2153,
                    "end": 2154,
                    "mention": "9",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 2156,
                    "end": 2158,
                    "mention": "11",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 2160,
                    "end": 2162,
                    "mention": "14",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "",
            "ref_spans": [
                {
                    "start": 630,
                    "end": 638,
                    "mention": "Figure 1",
                    "ref_id": null
                }
            ]
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Ebola by the numbers: The size, spread and cost of an outbreak.",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Butler",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Morello",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nature.",
            "volume": "514",
            "issn": "7522",
            "pages": "284-5",
            "other_ids": {
                "DOI": [
                    "10.1038/514284a"
                ]
            }
        },
        "BIBREF1": {
            "title": "A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus [v2; ref status: indexed,\nhttp://f1000r.es/4wt].",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ekins",
                    "suffix": ""
                },
                {
                    "first": "JS",
                    "middle": [],
                    "last": "Freundlich",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Coffee",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "F1000Res.",
            "volume": "3",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.12688/f1000research.5741.2"
                ]
            }
        },
        "BIBREF2": {
            "title": "Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v2; ref status: indexed,\nhttp://f1000r.es/53d].",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Veljkovic",
                    "suffix": ""
                },
                {
                    "first": "PM",
                    "middle": [],
                    "last": "Loiseau",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Figadere",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "F1000Res.",
            "volume": "4",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.12688/f1000research.6110.2"
                ]
            }
        },
        "BIBREF3": {
            "title": "Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kouznetsova",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Mart\u00ednez-Romero",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Emerg Microbes Infect.",
            "volume": "3",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1038/emi.2014.88"
                ]
            }
        },
        "BIBREF4": {
            "title": "Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [v2; ref status: awaiting peer review,\nhttp://f1000r.es/52g].",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Long",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wright",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Molesti",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "F1000Res.",
            "volume": "4",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.12688/f1000research.6085.2"
                ]
            }
        },
        "BIBREF5": {
            "title": "Small molecules with antiviral activity against the Ebola virus [v1; ref status: indexed,\nhttp://f1000r.es/523].",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Litterman",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lipinski",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ekins",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "F1000Res.",
            "volume": "4",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.12688/f1000research.6120.1"
                ]
            }
        },
        "BIBREF6": {
            "title": "Small molecule inhibitors of ebola virus infection.",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Picazo",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Giordanetto",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Drug Discov Today.",
            "volume": "20",
            "issn": "2",
            "pages": "277-286",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2014.12.010"
                ]
            }
        },
        "BIBREF7": {
            "title": "Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Elife.",
            "volume": "1",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.7554/eLife.00049"
                ]
            }
        },
        "BIBREF8": {
            "title": "Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition.",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ekins",
                    "suffix": ""
                },
                {
                    "first": "JE",
                    "middle": [],
                    "last": "Polli",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Eur J Pharm Sci.",
            "volume": "66C",
            "issn": "",
            "pages": "1-9",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ejps.2014.09.005"
                ]
            }
        },
        "BIBREF9": {
            "title": "\nIn silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.",
            "authors": [
                {
                    "first": "LL",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Cell Prolif.",
            "volume": "47",
            "issn": "4",
            "pages": "326-35",
            "other_ids": {
                "DOI": [
                    "10.1111/cpr.12117"
                ]
            }
        },
        "BIBREF10": {
            "title": "Expanding the scope of drug repurposing in pediatrics: the Children\u2019s Pharmacy Collaborative.",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Blatt",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Farag",
                    "suffix": ""
                },
                {
                    "first": "SJ",
                    "middle": [],
                    "last": "Corey",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Drug Discov Today.",
            "volume": "19",
            "issn": "11",
            "pages": "1696-1698",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2014.08.003"
                ]
            }
        },
        "BIBREF11": {
            "title": "Ebola in west Africa.",
            "authors": [
                {
                    "first": "MA",
                    "middle": [],
                    "last": "Trad",
                    "suffix": ""
                },
                {
                    "first": "DA",
                    "middle": [],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "PA",
                    "middle": [],
                    "last": "Tambyah",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Lancet Infect Dis.",
            "volume": "14",
            "issn": "11",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1016/S1473-3099(14)70924-7"
                ]
            }
        },
        "BIBREF12": {
            "title": "Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dyall",
                    "suffix": ""
                },
                {
                    "first": "CM",
                    "middle": [],
                    "last": "Coleman",
                    "suffix": ""
                },
                {
                    "first": "BJ",
                    "middle": [],
                    "last": "Hart",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antimicrob Agents Chemother.",
            "volume": "58",
            "issn": "8",
            "pages": "4885-93",
            "other_ids": {
                "DOI": [
                    "10.1128/AAC.03036-14"
                ]
            }
        },
        "BIBREF13": {
            "title": "The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Southall",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Sci Transl Med.",
            "volume": "3",
            "issn": "80",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/scitranslmed.3001862"
                ]
            }
        },
        "BIBREF14": {
            "title": "Drug repurposing: far beyond new targets for old drugs.",
            "authors": [
                {
                    "first": "TI",
                    "middle": [],
                    "last": "Oprea",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mestres",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "AAPS J.",
            "volume": "14",
            "issn": "4",
            "pages": "759-63",
            "other_ids": {
                "DOI": [
                    "10.1208/s12248-012-9390-1"
                ]
            }
        },
        "BIBREF15": {
            "title": "Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery.",
            "authors": [
                {
                    "first": "CT",
                    "middle": [],
                    "last": "Walsh",
                    "suffix": ""
                },
                {
                    "first": "MA",
                    "middle": [],
                    "last": "Fischbach",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Proc Natl Acad Sci U S A.",
            "volume": "106",
            "issn": "6",
            "pages": "1689-90",
            "other_ids": {
                "DOI": [
                    "10.1073/pnas.0813405106"
                ]
            }
        },
        "BIBREF16": {
            "title": "Exploiting drug-disease relationships for computational drug repositioning.",
            "authors": [
                {
                    "first": "JT",
                    "middle": [],
                    "last": "Dudley",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Deshpande",
                    "suffix": ""
                },
                {
                    "first": "AJ",
                    "middle": [],
                    "last": "Butte",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Brief Bioinform.",
            "volume": "12",
            "issn": "4",
            "pages": "303-11",
            "other_ids": {
                "DOI": [
                    "10.1093/bib/bbr013"
                ]
            }
        },
        "BIBREF17": {
            "title": "Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease.",
            "authors": [
                {
                    "first": "JT",
                    "middle": [],
                    "last": "Dudley",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sirota",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Shenoy",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Sci Transl Med.",
            "volume": "3",
            "issn": "96",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/scitranslmed.3002648"
                ]
            }
        },
        "BIBREF18": {
            "title": "\nIn silico repositioning of approved drugs for rare and neglected diseases.",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ekins",
                    "suffix": ""
                },
                {
                    "first": "AJ",
                    "middle": [],
                    "last": "Williams",
                    "suffix": ""
                },
                {
                    "first": "MD",
                    "middle": [],
                    "last": "Krasowski",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Drug Discov Today.",
            "volume": "16",
            "issn": "7\u20138",
            "pages": "298-310",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2011.02.016"
                ]
            }
        },
        "BIBREF19": {
            "title": "Finding small molecules for the \u2018next Ebola\u2019 [v1; ref status: awaiting peer review,\nhttp://f1000r.es/542].",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ekins",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Southan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Coffee",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "F1000Res.",
            "volume": "4",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.12688/f1000research.6181.1"
                ]
            }
        },
        "BIBREF20": {
            "title": "A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.",
            "authors": [
                {
                    "first": "PB",
                    "middle": [],
                    "last": "Madrid",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Chopra",
                    "suffix": ""
                },
                {
                    "first": "ID",
                    "middle": [],
                    "last": "Manger",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "PLoS One.",
            "volume": "8",
            "issn": "4",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1371/journal.pone.0060579"
                ]
            }
        },
        "BIBREF21": {
            "title": "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.",
            "authors": [
                {
                    "first": "AH",
                    "middle": [],
                    "last": "de Wilde",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jochmans",
                    "suffix": ""
                },
                {
                    "first": "CC",
                    "middle": [],
                    "last": "Posthuma",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antimicrob Agents Chemother.",
            "volume": "58",
            "issn": "8",
            "pages": "4875-84",
            "other_ids": {
                "DOI": [
                    "10.1128/AAC.03011-14"
                ]
            }
        },
        "BIBREF22": {
            "title": "Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Keyaerts",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Vijgen",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Antimicrob Agents Chemother.",
            "volume": "53",
            "issn": "8",
            "pages": "3416-21",
            "other_ids": {
                "DOI": [
                    "10.1128/AAC.01509-08"
                ]
            }
        },
        "BIBREF23": {
            "title": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.",
            "authors": [
                {
                    "first": "MJ",
                    "middle": [],
                    "last": "Vincent",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Bergeron",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Benjannet",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Virol J.",
            "volume": "2",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1186/1743-422X-2-69"
                ]
            }
        },
        "BIBREF24": {
            "title": "Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity.",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Boonyasuppayakorn",
                    "suffix": ""
                },
                {
                    "first": "ED",
                    "middle": [],
                    "last": "Reichert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Manzano",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antiviral Res.",
            "volume": "106",
            "issn": "",
            "pages": "125-34",
            "other_ids": {
                "DOI": [
                    "10.1016/j.antiviral.2014.03.014"
                ]
            }
        },
        "BIBREF25": {
            "title": "FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.",
            "authors": [
                {
                    "first": "LM",
                    "middle": [],
                    "last": "Johansen",
                    "suffix": ""
                },
                {
                    "first": "JM",
                    "middle": [],
                    "last": "Brannan",
                    "suffix": ""
                },
                {
                    "first": "SE",
                    "middle": [],
                    "last": "Delos",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Sci Transl Med.",
            "volume": "5",
            "issn": "190",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/scitranslmed.3005471"
                ]
            }
        },
        "BIBREF26": {
            "title": "The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Gehring",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rohrmann",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Atenchong",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Antimicrob Chemother.",
            "volume": "69",
            "issn": "8",
            "pages": "2123-31",
            "other_ids": {
                "DOI": [
                    "10.1093/jac/dku091"
                ]
            }
        }
    }
}